£2.0M
Deepbridge Capital provides follow-on funding to accelerate preclinical pipelines and targeted therapies.
Elasmogen
Elasmogen develops next generation biologics and soloMER therapeutics for targeted disease treatment.
£2.0MTotal raised
Elasmogen is a biopharmaceutical company developing next generation biologics known as soloMERs for site-specific drug delivery. The firm originates from research at the University of Aberdeen and focuses on treatments for inflammatory conditions and oncology.
Filed accounts
Cash at bank
Members only
Net assets
Members only
Shareholders' funds
Members only
Profit for the year
Members only
Employees
Members only
Cash, assets and headcount from Elasmogen's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Caroline Barelle
CEO
Caroline is the chief executive officer and founder of Elasmogen and sits on the Scottish Technology Council. She also serves as a board member for Opportunity North East and the Medicines Manufacturing Innovation Centre.
LinkedIn